meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative
1
mNSCLC - L1 - PDL1 positive
14
mNSCLC - L1 - TMB>10Mb
1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT)
6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus paclitaxel
pembrolizumab based treatment
pembrolizumab plus SoC
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs nab-paclitaxel
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs paclitaxel plus carboplatin
vs carboplatin plus nab-paclitaxel
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
Age < 65y (younger)
Age > 65y
ECOG 0
ECOG 1
Gender, female
Gender, male
PDL1 (TC0 and IC0 : <1% of TC and IC)
PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC)
PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC)
PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC )
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
TRAE leading to death (grade 5)
hepatitis (Autoimmune) AE (grade 3-4)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Colitis AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Epistaxis AE (grade 3-4)
Fatigue AE (grade 3-4)
Hyperthyroidism AE (grade 3-4)
Hypophysitis AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Infusion-related reaction AE (grade 3-4)
Myalgia AE (grade 3-4)
Nausea AE (grade 3-4)
Neutropenia AE (grade 3-4)
Peripheral neuropathy AE (grade 3-4)
Pneumonitis AE (grade 3-4)
Pyrexia AE (grade 3-4)
Severe skin reactions AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Thyroiditis AE (grade 3-4)
Vomiting AE (grade 3-4)
deaths (OS)
squamous - mNSCLC - L1 - all population
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC
1
certainty unassessable
statistically conclusive
-33%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open